Samik Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Samik Pharm makes finished prescription medicines, primarily chemically synthesised drugs for treating high blood pressure, high cholesterol, and diabetes, as well as over-the-counter products such as motion-sickness remedies and cold medicines.
Its drugs are dispensed through the prescription and retail pharmacy channels in Korea. Listed on KOSDAQ, Korea's small-cap and technology board, the company earns the largest share of its revenue from cardiovascular medicines, with contract manufacturing (CMO) services for other pharmaceutical companies forming a further meaningful revenue stream.
Summary is AI-generated and may contain errors · figures from DART filings
Alongside its own branded portfolio, the company operates a CMO business, manufacturing medicines on behalf of other pharmaceutical firms, currently serving dozens of client accounts across multiple drug categories.
Samik Pharm in five facts
What does Samik Pharm do?
Samik Pharm makes finished prescription medicines, primarily chemically synthesised drugs for treating high blood pressure, high cholesterol, and diabetes, as well as over-the-counter products such as motion-sickness remedies and cold medicines.
Where is Samik Pharm listed and in which sector?
Samik Pharm (Korean name: 삼익제약) trades under KRX code 014950 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Samik Pharm?
Its market capitalisation was US$63.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Samik Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Samik Pharm reported revenue of US$45.3M, operating profit of US$2.5M and a net loss of US$569.8K, per its annual report on DART (data retrieved from DART on 2026-10-02).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersSep 23
- Cash/in-kind dividend decision
Samik Pharm declared a cash dividend of US$0.03 per share.
Dividend · Feb 27 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Samik Pharm reported consolidated results for FY2025: revenue of US$41.9M (+7.5% year on year), operating profit of US$2.29M (−11% year on year) and a net loss of US$527K (from a profit a year earlier).
Earnings · Feb 27